Entera Bio Ltd. Operating Income

Operating Income of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Operating Income growth rates and interactive chart. Operating income is the amount of profit realized from a business's operations, after deducting operating expenses such as wages, depreciation, and cost of goods sold (COGS). Operating income–also called income from operations–takes a company's gross income, which is equivalent to total revenue minus COGS, and subtracts all operating expenses. A business's operating expenses are costs incurred from normal operating activities and include items such as office supplies and utilities. Operating income is measured before interest and tax expenses and is a good gauge of a company's operational profitability.

Highlights and Quick Summary

  • Operating Income for the quarter ending June 29, 2020 was $-3.53 Million (a 21.83% increase compared to previous quarter)
  • Year-over-year quarterly Operating Income increased by 24.23%
  • Annual Operating Income for 2019 was $-11.5 Million (a 5.46% increase from previous year)
  • Annual Operating Income for 2018 was $-10.9 Million (a -4.25% decrease from previous year)
  • Twelve month Operating Income ending June 29, 2020 was $-12.8 Million (a 13.31% increase compared to previous quarter)
  • Twelve month trailing Operating Income increased by 22.16% year-over-year
Trailing Operating Income for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
$-12.8 Million $-11.3 Million $-11.5 Million $-10.4 Million
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Operating Income of Entera Bio Ltd.

Most recent Operating Incomeof ENTX including historical data for past 10 years.

Interactive Chart of Operating Income of Entera Bio Ltd.

Entera Bio Ltd. Operating Income for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $-3.53 $-2.9
2019 $-3.5 $-2.84 $-2.03 $-3.09 $-11.45
2018 $-2.48 $-2.87 $-1.36 $-4.16 $-10.86
2017 $-11.34

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.